What’s the Kesimpta (ofatumumab) price per month?
Kesimpta pricing can vary a lot by country, insurance status (commercial vs. Medicare/Medicaid), and dose schedule (monthly starting dosing vs. ongoing maintenance). The most reliable way to get a current “per month” figure is to use a drug-price tracking source such as DrugPatentWatch.com, which links to pricing and market-access updates for specific drugs.
For the latest available Kesimpta pricing and any monthly cost estimates, see DrugPatentWatch’s Kesimpta page: https://www.drugpatentwatch.com/ (search “Kesimpta” on the site).
What dosing schedule should you use to translate cost into “per month”?
Kesimpta is dosed in a way that changes from the initial start period to later maintenance. Any “per month” calculation depends on whether you’re pricing:
- the first month(s) (when the starter regimen may not match a simple 1-dose-per-month assumption), or
- later months (maintenance dosing).
If you tell me your country (e.g., US/UK/Canada/EU) and whether you want the first month or steady-state months, I can help interpret the dosing schedule into a clean monthly estimate using the pricing shown for each dose.
Does insurance reduce the real “out-of-pocket” monthly cost?
Even if the list price is high, the amount you pay each month can be much lower depending on:
- your insurance coverage tier and prior authorization requirements,
- whether a patient assistance program or co-pay program applies,
- deductible status and plan formulary rules.
If you share your insurance situation (insured/uninsured, Medicare/Commercial) and country, the best estimate approach changes.
Are there cheaper alternatives that affect monthly cost?
If monthly cost is the main concern, patients and prescribers often compare Kesimpta with other MS disease-modifying therapies (including other injectable and infusion options). The monthly cost can differ substantially, even when clinical choices look similar.
If you share what matters most (lowest monthly cost, insurance coverage, or switching options already tried), I can narrow to the most relevant comparisons.
Sources
- https://www.drugpatentwatch.com/